ASCO: Desmoplastic Melanoma Responds to Neoadjuvant Pembrolizumab

TUESDAY, June 7, 2022 -- For patients with resectable desmoplastic melanoma (DM), pembrolizumab treatment prior to resection results in a high pathological complete response (pCR) rate, according to a study presented at the annual meeting of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news